We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
+$727M
Cap. Flow
+$234M
Cap. Flow %
7.95%
Top 10 Hldgs %
50.17%
Holding
105
New
24
Increased
24
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$134M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
3
TERN
Terns Pharmaceuticals
TERN
+$104M
4
ABVX
Abivax
ABVX
+$98.2M
5
MRK icon
Merck
MRK
+$72.7M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$104M
2
ASND icon
Ascendis Pharma A/S
ASND
+$87.8M
3
FOLD
Amicus Therapeutics
FOLD
+$76.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$70.3M
5
BDX icon
Becton Dickinson
BDX
+$60.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
76
MacroGenics
MGNX
$257M
$451K 0.02%
280,000
– –
APLT
77
DELISTED
Applied Therapeutics
APLT
– –
-14,250,000
Closed -$8.62M
ARQT icon
78
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-200,000
Closed -$3.77M
ATXS
79
DELISTED
Astria Therapeutics
ATXS
– –
-4,956,000
Closed -$36.1M
BDX icon
80
Becton Dickinson
BDX
$48.7B
– –
-325,000
Closed -$60.8M
BHVN icon
81
PUT
Biohaven
BHVN
$2.21B
– –
-701,700
Closed -$10.5M
BIIB icon
82
Biogen
BIIB
$30.7B
– –
-275,000
Closed -$38.5M
BLTE
83
Belite Bio
BLTE
$6.54B
– –
-312,500
Closed -$23.1M
BRKR icon
84
Bruker
BRKR
$8.14B
– –
-440,000
Closed -$14.3M
CDTX
85
DELISTED
Cidara Therapeutics
CDTX
– –
-400,000
Closed -$38.3M
CGON icon
86
CG Oncology
CGON
$6.62B
– –
-175,000
Closed -$7.05M
CRNX icon
87
Crinetics Pharmaceuticals
CRNX
$8.92B
– –
-750,000
Closed -$31.2M
CYTK icon
88
Cytokinetics
CYTK
$10.4B
– –
-725,000
Closed -$39.8M
DHR icon
89
Danaher
DHR
$144B
– –
-150,000
Closed -$29.7M
DNTH icon
90
Dianthus Therapeutics
DNTH
$6.09B
– –
-1,180,000
Closed -$46.4M
ESTA icon
91
Establishment Labs
ESTA
$2.28B
– –
-100,000
Closed -$4.1M
EXAS
92
DELISTED
Exact Sciences
EXAS
– –
-75,000
Closed -$4.1M
FOLD
93
DELISTED
Amicus Therapeutics
FOLD
– –
-9,750,000
Closed -$76.8M
GSK icon
94
GSK
GSK
$106B
– –
-125,000
Closed -$5.39M
INSP icon
95
Inspire Medical Systems
INSP
$1.74B
– –
-135,000
Closed -$10M
IONS icon
96
Ionis Pharmaceuticals
IONS
$9.4B
– –
-1,075,000
Closed -$70.3M
KOD icon
97
Kodiak Sciences
KOD
$2.84B
– –
-250,000
Closed -$4.09M
LUNG icon
98
Pulmonx
LUNG
$87.6M
– –
-830,000
Closed -$1.34M
QURE icon
99
uniQure
QURE
$3.22B
– –
-225,000
Closed -$13.1M
RARE icon
100
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-750,000
Closed -$22.6M
1 2 3
4
5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Vestal Point Capital held 105 positions worth $2.94B, up 33% from $2.21B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Vestal Point Capital deployed $234M of net new capital in Q4 2025, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Terns Pharmaceuticals: 4,500,000 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $104M trimmed.

  • Vestal Point Capital's largest Q4 2025 buy was Terns Pharmaceuticals: 4,500,000 shares worth $182M.
  • Vestal Point Capital added most to Arcellx in Q4 2025, an estimated $134M increase.
  • Vestal Point Capital's biggest Q4 2025 reduction was Nuvalent, cutting an estimated $104M.
  • Vestal Point Capital fully exited Amicus Therapeutics in Q4 2025, selling an estimated $76.8M.
  • Vestal Point Capital's ten largest holdings make up 50% of its $2.94B portfolio in Q4 2025.
  • Vestal Point Capital opened 24 new positions and closed 29 in Q4 2025.
  • Vestal Point Capital's portfolio value rose 33% quarter-over-quarter to $2.94B.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.